Lisata Therapeutics to Announce Q1 2024 Financial Results and Business Update on May 9, 2024

BASKING RIDGE, N.J., May 02, 2024 - Lisata Therapeutics, Inc. (Nasdaq: LSTA) is set to report its financial outcomes for the first quarter of 2024 on May 9, 2024, after the market closes. The company will also conduct a conference call the same day at 4:30 p.m. Eastern Time. Participants are required to register through a provided link to receive the necessary details for joining the call. It is advisable for participants to dial in 15 minutes prior to the start time to avoid any delays. Moreover, a live webcast of the conference call will be available on the Investors & News section of Lisata's website, with a replay option accessible for 12 months starting two hours after the call concludes.

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative treatments for advanced solid tumors and other serious diseases. The company's leading product, certepetide, is an investigational drug aimed at enhancing the effectiveness of anti-cancer drugs by activating a novel uptake pathway that allows these drugs to better target and penetrate solid tumors. This product is based on Lisata’s proprietary CendR Platform® Technology.

Lisata has established several significant commercial and research partnerships and plans to announce multiple clinical study and business milestones over the next two years. The company has indicated that its current business and development plan is sufficiently funded with available capital through these milestones and into early 2026. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!